Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Carcinoma, Transitional Cell 3Urinary Bladder Neoplasms 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Colorectal Neoplasms 2Carcinoma 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Platinum-resistant Ovarian Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasm, Residual 1Neoplasm Metastasis 1Microsatellite Instability 1Melanoma 1Lung Neoplasms 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Temozolomide 100Radiotherapy 49Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 22Bevacizumab 22Lomustine 16Nivolumab 14Surgical Procedures, Operative 10atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × ALT-803 × 1 year × Clear all
NCT06061809 2026-02-12

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

ImmunityBio, Inc.

Phase 2 Recruiting
34 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡